Alkermes Plc news

   Watch this stock
Showing stories 1 - 10 of about 87   

Articles published

ALKS 58.07 -0.61 (-1.04%)
price chart
Alkermes May Have Lucky Investors Doing A Happy Jig
Ireland-based Alkermes PLC (NASDAQ:ALKS) started as a royalty-based company that reformulated existing drugs into extended release microsphere agents.
Contrasting Delcath Systems (DCTH) & Alkermes PLC (ALKS)  The Cerbat Gem
Alkermes PLC (ALKS) Position Raised by BlackRock Inc.  Sports Perspectives
Alkermes (ALKS) Up 2.5% Since Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Alkermes PLC ALKS . Shares have added about 2.5% in that time frame, outperforming the market.
Alkermes plc (ALKS) Moves Lower on Volume Spike for June 05  Equities.com
Will Alkermes Plc Ord (NASDAQ:ALKS) Run Out of Steam Soon? Short Interest Is ...  KL Daily
Active Runner in Focus: Alkermes Plc (ALKS)
Shares of Alkermes Plc (ALKS) is moving on volatility today 0.64% or 0.37 rom the open. The NASDAQ listed company saw a recent bid of 58.03 on 26185 volume.
Alkermes plc (ALKS) Names Craig Hopkinson, MD, as CMO, SVP
Alkermes plc (NASDAQ: ALKS) today announced the appointment of Craig Hopkinson, M.D., as Chief Medical Officer, and Senior Vice President of Clinical Development and Medical Affairs.
United Services Automobile Association Increases Stake in Alkermes Plc (ALKS ...
United Services Automobile Association increased its stake in Alkermes Plc (ALKS) by 25.54% based on its latest 2016Q4 regulatory filing with the SEC.
Alkermes Looks To Capitalize On Opioid Epidemic Through Aggressive Lobbying
The U.S. Food and Drug Administration's quest to address the growing opioid crisis is hurting many pharmaceutical companies, including Endo International plc - Ordinary Shares (NASDAQ: ENDP), presenting an opportunity for companies like Alkermes Plc ...
Alkermes plc (ALKS) Initiates Study 217 for ALKS 5461 for MDD
Alkermes plc (NASDAQ: ALKS) today announced the initiation of study 217, a phase 3b trial of ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD).
Alkermes plc (ALKS) Commences Phase 3 Study of ALKS 3831 in Young Adult Patients
Alkermes plc (NASDAQ: ALKS) today announced the initiation of ENLIGHTEN-Early, a supportive study in the ENLIGHTEN clinical development program for ALKS 3831, an investigational, novel, once-daily, oral atypical antipsychotic drug candidate designed ...
Risk Malaise Alert in Option Market: Alkermes PLC Implied Price Swing Hits A ...
Before we dive into any analysis we simply note that Alkermes PLC (NASDAQ:ALKS) risk is actually priced pretty low by the option market as of right now.
Is Alkermes plc (ALKS) worth $57.71 based on its intrinsic value?
In this article I am going to calculate the intrinsic value of Alkermes (NASDAQ:ALKS) by estimating the Future Cash Flows and discounting them to their present value.